Stock PRQR PROQR THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Real-time Estimate Cboe BZX
Other stock markets
 03:27:30 2024-04-19 pm EDT 		5-day change 1st Jan Change
1.955 USD +5.11% Intraday chart for ProQR Therapeutics N.V. -10.00% 0.00%
Mar. 14 Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating MT
Mar. 13 ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PROQR THERAPEUTICS N.V. Stock ProQR Therapeutics N.V.
0.00% 151M
C
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.75% 102B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.73% 96.07B
B+
ARGENX SE Stock argenx SE
-1.80% 21.66B
B
BIONTECH SE Stock BioNTech SE
-17.46% 20.77B
B+
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-27.83% 13.79B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
-1.11% 13.33B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.29% 10.94B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PRQR Stock
  4. Ratings ProQR Therapeutics N.V.